IDEXX Laboratories - IDXX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $580.38
  • Forecasted Upside: 12.45%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$516.10
▼ -1.84 (-0.36%)

This chart shows the closing price for IDXX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IDEXX Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDXX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDXX

Analyst Price Target is $580.38
▲ +12.45% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for IDEXX Laboratories in the last 3 months. The average price target is $580.38, with a high forecast of $650.00 and a low forecast of $460.00. The average price target represents a 12.45% upside from the last price of $516.10.

This chart shows the closing price for IDXX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 polled investment analysts is to moderate buy stock in IDEXX Laboratories. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/30/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/23/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2024Morgan StanleyLower TargetOverweight ➝ Overweight$620.00 ➝ $596.00Low
5/2/2024BarclaysLower TargetOverweight ➝ Overweight$655.00 ➝ $570.00Low
4/9/2024William BlairReiterated RatingOutperformLow
2/6/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$600.00 ➝ $630.00Low
2/6/2024BarclaysBoost TargetOverweight ➝ Overweight$605.00 ➝ $655.00Low
1/30/2024Piper SandlerDowngradeOverweight ➝ Neutral$525.00Low
1/17/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$500.00 ➝ $650.00Low
1/5/2024William BlairReiterated RatingOutperformLow
12/7/2023BNP ParibasInitiated CoverageOutperform$602.00Low
11/6/2023Piper SandlerBoost TargetOverweight ➝ Overweight$520.00 ➝ $525.00Low
11/3/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$578.00 ➝ $500.00Low
11/2/2023BarclaysBoost TargetOverweight ➝ Overweight$590.00 ➝ $592.00N/A
11/2/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$600.00 ➝ $550.00Low
10/30/2023Stifel NicolausLower TargetHold ➝ Hold$500.00 ➝ $460.00Low
10/5/2023Piper SandlerLower Target$600.00 ➝ $520.00Low
9/15/2023Stifel NicolausLower TargetHold ➝ Hold$525.00 ➝ $500.00Low
8/3/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$590.00 ➝ $600.00Low
8/2/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$550.00 ➝ $600.00N/A
8/2/2023Atlantic SecuritiesDowngradeOverweight ➝ Neutral$610.00Low
3/23/2023Morgan StanleyBoost TargetOverweight$543.00 ➝ $590.00Low
2/8/2023BarclaysBoost TargetOverweight$582.00 ➝ $590.00Low
2/7/2023JPMorgan Chase & Co.Boost TargetOverweight$525.00 ➝ $550.00Low
2/7/2023Atlantic SecuritiesBoost TargetOverweight$470.00 ➝ $600.00Low
1/25/2023The Goldman Sachs GroupBoost TargetBuy$465.00 ➝ $530.00Low
11/15/2022Morgan StanleyLower TargetOverweight$573.00 ➝ $543.00Low
11/2/2022Atlantic SecuritiesLower TargetOverweight$490.00 ➝ $470.00Low
10/17/2022JPMorgan Chase & Co.Lower TargetOverweight$525.00 ➝ $450.00Low
8/8/2022Piper SandlerLower Target$500.00 ➝ $420.00Low
8/5/2022BarclaysLower TargetOverweight$700.00 ➝ $582.00Low
8/4/2022Morgan StanleyLower TargetOverweight$603.00 ➝ $573.00N/A
8/3/2022Stifel NicolausDowngradeBuy ➝ Hold$415.00Low
8/3/2022Atlantic SecuritiesLower TargetOverweight$500.00 ➝ $490.00Low
7/26/2022Piper SandlerLower TargetOverweight$440.00 ➝ $420.00Low
7/25/2022Stifel NicolausDowngradeBuy ➝ Hold$415.00Low
7/21/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$530.00 ➝ $435.00Low
7/11/2022Piper SandlerInitiated CoverageOverweight$440.00N/A
6/24/2022Stifel NicolausLower TargetBuy$575.00 ➝ $500.00Low
5/19/2022The Goldman Sachs GroupLower TargetNeutral$615.00 ➝ $530.00Low
5/5/2022Bank of AmericaDowngradeBuy ➝ Neutral$550.00 ➝ $470.00High
2/8/2022Atlantic SecuritiesInitiated CoverageOverweight$650.00Low
2/2/2022William BlairReiterated RatingOutperformLow
11/18/2021Morgan StanleyInitiated CoverageOverweight$732.00Medium
8/13/2021Credit Suisse GroupBoost TargetOutperform$735.00 ➝ $770.00Low
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$735.00Medium
8/3/2021The Goldman Sachs GroupBoost TargetNeutral$550.00 ➝ $610.00Medium
8/2/2021BarclaysBoost TargetOverweight$616.00 ➝ $750.00Low
7/12/2021GuggenheimDowngradeBuy ➝ NeutralMedium
5/5/2021BarclaysBoost TargetOverweight$600.00 ➝ $616.00Low
2/17/2021BarclaysInitiated CoverageOverweight$600.00Low
1/29/2021JPMorgan Chase & Co.Initiated CoverageOverweight$570.00Low
8/17/2020Credit Suisse GroupBoost TargetOutperform$415.00 ➝ $422.00Low
8/4/2020Credit Suisse GroupBoost TargetOutperform$300.00 ➝ $415.00Low
7/30/2020Stifel NicolausBoost TargetBuy$280.00 ➝ $375.00Low
7/20/2020Bank of AmericaBoost TargetBuy$300.00 ➝ $390.00Medium
5/1/2020Stifel NicolausBoost TargetBuy$266.00 ➝ $280.00Medium
11/1/2019GuggenheimSet TargetBuy$310.00Low
9/9/2019The Goldman Sachs GroupInitiated CoverageNeutral$277.00High
8/16/2019Credit Suisse GroupBoost TargetOutperform$282.00 ➝ $293.00Low
7/22/2019Stifel NicolausBoost TargetBuy$255.00 ➝ $295.00Low
6/21/2019Bank of AmericaSet TargetBuy$300.00Low
5/23/2019GuggenheimInitiated CoverageBuy ➝ Buy$276.00Medium
(Data available from 5/23/2019 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 20 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/26/2023
  • 11 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
11/25/2023
  • 19 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/25/2023
  • 23 very positive mentions
  • 28 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
1/24/2024
  • 45 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/23/2024
  • 26 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2024
  • 19 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2024
  • 30 very positive mentions
  • 20 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
5/23/2024

Current Sentiment

  • 30 very positive mentions
  • 20 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

IDEXX Laboratories logo
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More

Today's Range

Now: $516.10
Low: $511.78
High: $524.82

50 Day Range

MA: $510.61
Low: $468.04
High: $548.53

52 Week Range

Now: $516.10
Low: $372.50
High: $583.39

Volume

503,707 shs

Average Volume

453,834 shs

Market Capitalization

$42.62 billion

P/E Ratio

49.96

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of IDEXX Laboratories?

The following Wall Street research analysts have issued reports on IDEXX Laboratories in the last year: Atlantic Securities, Barclays PLC, BNP Paribas, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for IDXX.

What is the current price target for IDEXX Laboratories?

8 Wall Street analysts have set twelve-month price targets for IDEXX Laboratories in the last year. Their average twelve-month price target is $580.38, suggesting a possible upside of 11.6%. The Goldman Sachs Group, Inc. has the highest price target set, predicting IDXX will reach $650.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $460.00 for IDEXX Laboratories in the next year.
View the latest price targets for IDXX.

What is the current consensus analyst rating for IDEXX Laboratories?

IDEXX Laboratories currently has 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IDXX.

What other companies compete with IDEXX Laboratories?

Other companies that are similar to IDEXX Laboratories include Humana, Alcon, Centene, IQVIA and Takeda Pharmaceutical. Learn More about companies similar to IDEXX Laboratories.

How do I contact IDEXX Laboratories' investor relations team?

IDEXX Laboratories' physical mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company's listed phone number is (207) 556-0300 and its investor relations email address is [email protected]. The official website for IDEXX Laboratories is www.idexx.com. Learn More about contacing IDEXX Laboratories investor relations.